In the latest episode of “TRUTH” with Robert F. Kennedy, Jr., Kennedy discussed the current state of treatment options for COVID-19 with Peter McCullough, M.D., MPH.
McCullough, vice chief of internal medicine at Baylor University Medical Center, provided testimony on Nov. 19, 2020, on potential COVID treatments during the Senate’s Homeland Security and Governmental Affairs Committee hearings, Early Outpatient Treatment: An Essential Part of a COVID-19 Solution.
- Promising COVID treatments are being sabotaged by government health agencies.
- Age structures of countries are significant factors in variances we’re seeing in death rates around the globe.
- McCullough believes that as many as 85% of COVID deaths could have been prevented through early treatment.
LISTEN TO THIS CRITICAL INTERVIEW
- Fear and anxiety have led to “therapeutic nihilism” in dealing with the COVID crisis as efforts are being focused on vaccination only, while the Hippocratic Oath is being ignored.
- For patients whose doctors don’t provide actual COVID treatments, McCullough recommends “A Guide to Home-Based COVID Treatment,” published by the Association of American Physicians and Surgeons.
Peter A. McCullough, MD, MPH COVID-19 Treatment Protocols
Treatment Publication: Peter A. McCullough, M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center, et al. published an article in the American Journal of Medicine, August 2020: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.
The Great Reset 2021 - AAPS News
Great “resets”—or revolutions—aim to destroy the old order and rebuild from scratch. Books have been burned, monuments torn down, streets and cities renamed. The French revolutionaries even abolished the seven-day week, renamed months, and designated 1792, when the National Convention had proclaimed France a republic, to be year 1.
************************************************************
By Michael Rectenwald
ADVERSE REACTIONS
When adverse reactions to vaccination are reported in the news, they are dismissed as a tiny percentage of those who are vaccinated. We do not know that for sure as there is no accurate way for all adverse reactions to be reported for an accurate count. We post here a number of seminal articles and videos which should help people come cope with the Brave New World of World Wide Vaccination, the very special dream of Bill Gates.
‘Inactive’ Ingredients in COVID Vaccines and Allergic Reactions
COVID vaccine makers have not only introduced new primary ingredients to the U.S. vaccine stage, but they’ve bundled these new ingredients with “inactive” ingredients in unprecedented ways that raise the risk for dangerous allergic reactions.
The Centers for Disease Control and Prevention (CDC) claims that vaccines “use only the ingredients they need to be as safe and effective as possible.” The star of the show in any vaccine is the “active” ingredient, which is the one designed to create an antibody response.
But the other, supposedly “inactive” ingredients — known as excipients — also play significant, and in many cases risky, co-starring roles.
Studies of licensed vaccines have identified many problems with these secondary ingredients — adjuvants like aluminum, preservatives like thimerosal and stabilizers like gelatin — not to mention highlighting the presence in vaccines of residual DNA from cell lines used in the manufacturing process as well as disclosed and undisclosed contaminants.
With the advent of three experimental COVID injections approved for emergency use in the U.S., manufacturers have introduced new primary ingredients to the U.S. vaccine stage — messenger RNA (mRNA) in the Pfizer and Moderna injections and an adenovirus vector in the Johnson & Johnson (J&J) injection.
Not only that, but vaccine makers have bundled these new primary ingredients with “inactive” excipients in unprecedented ways — polyethylene glycol (PEG) in the case of the mRNA vaccines and polysorbate 80 in the J&J shot.
PEGs and polysorbates are structurally similar and are also sometimes combined in a PEG-polysorbate 80 mixture that is “substantially the same as that of … pure PEG.” Pre-COVID, both compounds had already been flagged for their ability to cross-react and produce immediate hypersensitivity reactions, a type of “exaggerated or inappropriate” immune response that can include anaphylaxis.
Given that at least 1,689 recipients of the Pfizer and Moderna injections have reported anaphylactic or serious allergic reactions (as of March 5), and that two J&J clinical trial participants also suffered severe allergic reactions, some allergy experts are recommending that closer attention be directed to the risks of both excipients.
Hypersensitivity to structurally similar excipients
Children’s Health Defense has written extensively about the risks of PEG, the coating for the lipid nanoparticle RNA delivery system in the Pfizer and Moderna injections. Two recent studies echo some of the concerns we raised.
Writing in The New England Journal of Medicine (NEJM) in February, physician-researchers Mariana Castells (Brigham and Women’s Hospital) and Elizabeth Phillips (Vanderbilt University) note that “no other vaccine that has PEG as an excipient has [ever] been in widespread use” until COVID. The two authors then zero in on the evidence linking PEG to anaphylaxis, suggesting that it may represent a “hidden danger.”
Dr. Andrew Wakefield 1986 The Act: Vaccines and Non-Liability
Dr Andrew Wakefield was the foremost enterologist in The United Kingdom until he was viciously attacked by the Vaccine Industry for making a discovery concerning the effect of the MMR Vaccine causing Irritable Bowel Syndrome in vaccinated children.
Dr. Mercola Interviews Dr. Andrew Wakefield
Geert Varden Bossche
The following document is a key update of my executive summary and addresses important questions, comments and replies that have been raised on my emergency appeal of global concern. I repeat with utmost urgency my call for a public scientific debate with the WHO, qualified experts and authorities worldwide
Vanden Bossche’s ‘hockey stick’ hypothesis
With Alliance for Natural Health’s founder, Rob Verkerk Ph.D., now having spent several hours in discussion with Vanden Bossche, we are now of the view that it would be scientifically, socially and ethically irresponsible to dismiss Vanden Bossche’s concerns. The key one is that the current COVID control strategies, including the global mass vaccination program, will create an “uncontrollable monster.”
In summary, the concerns center around the notion that a combination of lockdowns and extreme selection pressure on the virus induced by the intense global mass vaccination program might diminish the number of cases, hospitalizations and deaths in the short-term, but ultimately, will induce the creation of more mutants of concern.
This is the result of what Vanden Bossche calls ‘immune escape’ (i.e. incomplete sterilization of the virus by the human immune system, even following vaccine administration). This will in turn trigger vaccine companies to further refine vaccines that will add, not reduce, the selection pressure, so producing ever more transmissible and potentially deadly variants.
The selection pressure will cause greater convergence in mutations that affect the critical spike protein of the virus that is responsible for breaking through the mucosal surfaces of our airways, the route used by the virus to enter the human body. The virus will effectively outsmart the highly specific antigen-based vaccines that are being used and tweaked, dependent on the circulating variants. All of this could lead to a hockey stick-like increase in serious and potentially lethal cases — in effect, an out-of-control pandemic.
Not only that, it will be Western nations with high proportions of metabolically diseased, overweight or obese individuals with compromised immune systems that will be hit hardest.
- Kai Kupferschmidt
- Science 22 Jan 2021:
Vol. 371, Issue 6527, pp. 329-330
DOI: 10.1126/science.371.6527.329
When the number of COVID-19 cases began to rise again in Manaus, Brazil, in December 2020, Nuno Faria was stunned. The virologist at Imperial College London had just co-authored a paper in Science estimating that three-quarters of the city's inhabitants had already been infected with SARS-CoV-2, the pandemic coronavirus—more than enough, it seemed, for herd immunity to develop. The virus should be done with Manaus. Yet hospitals were filling up again. “It was hard to reconcile these two things,” Faria says. He started to hunt for samples he could sequence to find out whether changes in the virus could explain the resurgence.
On 12 January, Faria and his colleagues posted their initial conclusions on the website virological.org. Thirteen of 31 samples collected in mid-December in Manaus turned out to be part of a new viral lineage they called P.1. Much more research is needed, but they say one possibility is that in some people, P.1 eludes the human immune response triggered by the lineage that ravaged the city earlier in 2020.
Emerging variants of the coronavirus have been in the news ever since scientists raised the alarm over B.1.1.7, a SARS-CoV-2 variant that first caught scientists' attention in England in December and that is more transmissible than previously circulating viruses (Science, 8 January, p. 108). But now, they're also focusing on a potential new threat: variants that could do an end run around the human immune response. Such “immune escapes” could mean more people who have had COVID-19 remain susceptible to reinfection, and that proven vaccines may, at some point, need an update.
...
The more transmissible variant, B.1.1.7, is already spreading rapidly in the United Kingdom, Ireland, and Denmark, and probably in many other countries. But scientists are just as worried about 501Y.V2, a variant detected in South Africa. Some of the mutations it carries, including ones named E484K and K417N, change its surface protein, spike, and have been shown in the lab to reduce how well monoclonal antibodies combat the virus. In a preprint published earlier this month, Jesse Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center, showed that E484K also reduced the potency of convalescent sera from some donors 10-fold—although he is quick to add this does not necessarily mean the mutation would cause people's immunity to the new strain to drop 10-fold.
P.1 adds to the concerns because it appears to have hit on a similar constellation of mutations and has emerged in a place with a high level of immunity. “Anytime you see the same mutations arising and starting to spread multiple times, in different viral strains across the world, that's really strong evidence that there's some evolutionary advantage to those mutations,” Bloom says.
Like B.1.1.7, the Brazilian variant is already on the move. Just as Faria was finishing his analysis of the Brazilian genomes, a report was published of a variant detected in travelers arriving in Japan from Brazil—and it turned out to be P.1. (As Science went to press, U.S. researchers also reported several new variants, but their importance remained unclear.)
